Please ensure Javascript is enabled for purposes of website accessibility

Why TransEnterix Stock Is Soaring Today

By George Budwell - Oct 17, 2017 at 12:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

TransEnterix's stock keeps moving higher in the wake of the FDA clearing its novel robotic surgery device.

What happened

Shares of the robotic-surgery company TransEnterix (ASXC -0.36%) rose by as much as 69% today in early morning trading. This small-cap healthcare stock has now appreciated by over 200% since the U.S. Food and Drug Administration, or FDA, approved its Senhance Surgical Robotic System just last Friday.

Picture of a rocket taking flight.

Image source: Getty Images.

So what

TransEnterix's Senhance Surgical Robotic System is designed to compete directly with Intuitive Surgical's (ISRG -0.49%) market-leading da Vinci system. Although there's no guarantee of success, the commercial opportunity presented by the rapidly growing robotic surgery market is absolutely immense, to put it mildly. 

Since launching the da Vinci system in 2000, for instance, Intuitive has seen its flagship device regularly rake in over $800 million a year in new system sales. So, TransEnterix arguably only needs to capture a tiny slice of this sizable market to justify its current valuation -- implying that there may be plenty of upside remaining in this surging biotech stock going forward. 

Now what

After this major regulatory win, it wouldn't be all that surprising if TransEnterix ends up fetching a handsome buyout offer from the likes of either Intuitive Surgical, or perhaps Johnson & Johnson (JNJ -0.53%). J&J, after all, has been looking for a way to make a big splash in the high-growth robotic surgery market, and the Senhance Surgical Robotic System may be the perfect opportunity to do just that.

A buyout also makes a lot of sense for TransEnterix -- that is, if the right offer comes along. With less than $30 million in cash at the end of the most recent quarter, after all, TransEnterix doesn't really have the necessary financial resources to take on an embedded competitor like Intuitive Surgical. 

Bottom line: TransEnterix's radical revaluation is certainly justifiable in light of Senhance's healthy commercial opportunity -- but the company will undoubtedly need to address its weak financial position soon. To do so, TransEnterix may choose to either sell itself to a deep-pocketed company like J&J, or tap the public markets to raise capital. Either way, growth investors may want to keep a close eye on this emerging robotic surgery company in the days and years ahead. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Intuitive Surgical and Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
$0.56 (-0.36%) $0.00
Johnson & Johnson Stock Quote
Johnson & Johnson
$170.20 (-0.53%) $0.91
Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
$239.13 (-0.49%) $-1.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.